Literature DB >> 17936368

Abnormal Tr1 differentiation in multiple sclerosis.

Anne L Astier1, David A Hafler.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). In the recent years, accumulating evidence has supported an immunosuppressive role for regulatory T cells (Tregs). Most studies in the context of autoimmunity have focused on the defects of the CD4+CD25 high Tregs. However, we recently demonstrated an altered function of Tr1 Treg cells in MS, characterized by a lack of IL-10 secretion. Therefore, several major regulatory T cell defects are involved in human autoimmune disease. Hence, the induction of Tregs or the stimulation of Treg activity may be beneficial for the treatment of such diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936368      PMCID: PMC2200628          DOI: 10.1016/j.jneuroim.2007.09.018

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  109 in total

1.  Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61.

Authors:  A McNeill; E Spittle; B T Bäckström
Journal:  Scand J Immunol       Date:  2007-01       Impact factor: 3.487

2.  GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype.

Authors:  Debra A MacKenzie; Jill Schartner; Jack Lin; Amanda Timmel; Martha Jennens-Clough; C Garrison Fathman; Christine M Seroogy
Journal:  J Biol Chem       Date:  2007-01-26       Impact factor: 5.157

3.  Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients.

Authors:  Roberto Alvarez-Lafuente; Marta García-Montojo; Virginia De las Heras; Manuel Bartolomé; Rafael Arroyo
Journal:  J Clin Virol       Date:  2006-12       Impact factor: 3.168

4.  Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene.

Authors:  A A Vandenbark; T Finn; D Barnes; N Culbertson; Y K Chou; K Hicks; A Bakke; M Mass; R Whitham; H Offner; D Bourdette
Journal:  J Neurosci Res       Date:  2001-10-15       Impact factor: 4.164

5.  Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.

Authors:  L A Stephens; C Mottet; D Mason; F Powrie
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

Review 6.  Multiple sclerosis: a battle between destruction and repair.

Authors:  Jonathan L McQualter; Claude C A Bernard
Journal:  J Neurochem       Date:  2006-11-13       Impact factor: 5.372

7.  IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells.

Authors:  M K Levings; R Sangregorio; F Galbiati; S Squadrone; R de Waal Malefyt; M G Roncarolo
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

8.  Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.

Authors:  D Dieckmann; H Plottner; S Berchtold; T Berger; G Schuler
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

View more
  30 in total

Review 1.  Tolerance regeneration by T regulatory cells in autologous haematopoietic stem cell transplantation for autoimmune diseases.

Authors:  Kevin Hendrawan; Malini Visweswaran; David D F Ma; John J Moore
Journal:  Bone Marrow Transplant       Date:  2019-10-16       Impact factor: 5.483

Review 2.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

Review 3.  CD46 plasticity and its inflammatory bias in multiple sclerosis.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-01-26       Impact factor: 4.291

Review 4.  Regulatory T cells in autoimmune neuroinflammation.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

5.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 6.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

7.  Regulatory B Cells Induce Formation of IL-10-Expressing T Cells in Mice with Autoimmune Neuroinflammation.

Authors:  Andrea Pennati; Spencer Ng; Yuanqiang Wu; Jordan R Murphy; Jiusheng Deng; Srikant Rangaraju; Seneshaw Asress; Jennifer L Blanchfield; Brian Evavold; Jacques Galipeau
Journal:  J Neurosci       Date:  2016-11-07       Impact factor: 6.167

8.  Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis.

Authors:  Adi Vaknin-Dembinsky; Gopal Murugaiyan; David A Hafler; Anne L Astier; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2008-04-10       Impact factor: 3.478

Review 9.  Toll-like receptor signalling on Tregs: to suppress or not to suppress?

Authors:  Wendy W C van Maren; Joannes F M Jacobs; I Jolanda M de Vries; Stefan Nierkens; Gosse J Adema
Journal:  Immunology       Date:  2008-06-28       Impact factor: 7.397

10.  Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.

Authors:  Lorenzo Dagna; Joshua C Pritchett; Paolo Lusso
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.